| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: SDS-PAGE Purity =99.3%
| Targets |
OVA is used as a model allergen/antigen, not a drug targeting a specific molecular target
|
|---|---|
| ln Vivo |
Ovalbumins (OVA) (Silica nanoparticles): 1 mg/kg, six intranasal injections spread over two weeksSNP/OVA Coadministration of SNP resulted in considerable airway allergic inflammation in the female BALB/c mouse model, which was accompanied by an increase in eosinophils and lymphocytes as well as total cells, macrophages, and neutrophils [1].
In a mouse model of allergic airway inflammation, intranasal administration of ovalbumin (OVA, 1 mg/kg per treatment, six times over 2 weeks) alone (saline/OVA group) did not induce significant airway hyper-responsiveness (AHR), inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF), or pathological changes compared to the control group. [1] When co-administered with silica nanoparticles (SNPs), OVA (1 mg/kg per treatment, six times over 2 weeks) induced significant adjuvant effects, including increased AHR, increased total cell counts (macrophages, lymphocytes, eosinophils, neutrophils) in BALF, peribronchial and perivascular inflammation, goblet cell metaplasia (PAS staining), and elevated levels of cytokines IL-5, IL-13, IL-1β, and IFN-γ in lung homogenates. [1] |
| Enzyme Assay |
To evaluate the toxic and adjuvant effects of 3 types of SNPs in the airway system, six-week-old female BALB/c mice were intranasally administered 3 types of SNPs (spherical [S-SNP], mesoporous [M-SNP], and polyethylene glycol-conjugated [P-SNP]) alone or SNPs/ovalbumin (OVA), three times weekly for 2 weeks. Airway hyper-responsiveness (AHR), bronchoalveolar lavage fluid (BALF), cytokine levels, and histology of the lungs were analyzed.
|
| Animal Protocol |
Female BALB/c mice, 5–6 weeks old, were purchased. SNPs alone and SNP/OVA model were used 5 mice for each group. All mice were maintained at conventional animal facilities under standard conditions (room temperature of 21–24 °C and relative humidity of 45–70 %, with a 12 h light/dark cycle), and all experimental protocols were approved by the Department of Laboratory Animal Resources, Yonsei Biomedical Research institute, Yonsei University College of Medicine. The present study was approved by the guide for the care and use of laboratory animal guide line. SNPs sized 100 nm were administered via intranasal inoculation of 10 mg/kg per treatment (SNP direct toxicity model, Experiment 1, Fig. 2a) and SNPs 10 mg/kg per treatment and OVA 1 mg/kg (SNP/OVA model, Experiment 2, Fig. 2b) were administered 6 times over 2 weeks[1].
Six-week-old female BALB/c mice were used. For the SNP/OVA adjuvant effect model, mice were administered ovalbumin (OVA) at a dose of 1 mg/kg per treatment (EndoFit Ovalbumin, low endotoxin) via intranasal inoculation. OVA was administered together with SNPs (10 mg/kg per treatment) three times weekly for 2 weeks (total of 6 administrations). The saline/OVA group received OVA alone. AHR was measured 48 hours after the last challenge using a forced oscillation technique (FlexiVent) in response to aerosolized methacholine (3.125–50.0 mg/mL). [1] |
| Toxicity/Toxicokinetics |
In this study, ovalbumin (OVA) alone (saline/OVA group) did not induce significant airway inflammation, AHR, or pathological changes, indicating that at the dose and route used (1 mg/kg, intranasal, six times over 2 weeks), OVA was not toxic to the airway system in the absence of an adjuvant. [1]
|
| References |
[1]. Toxic and adjuvant effects of silica nanoparticles on ovalbumin-induced allergic airway inflammation in mice. Respir Res. 2016 May 18;17(1):60.
|
| Additional Infomation |
Ovalbumin (OVA) is used in this study as a model allergen to evaluate the adjuvant effects of silica nanoparticles (SNPs) in inducing allergic airway inflammation. OVA alone did not induce allergic airway inflammation, but co-exposure with SNPs significantly enhanced allergic responses, demonstrating that SNPs have an adjuvant effect for OVA sensitization. [1]
|
| CAS # |
9006-59-1
|
|---|---|
| PubChem CID |
3277971
|
| Appearance |
White to light yellow solid
|
| Melting Point |
60°C
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UOXVFQCRPDLSFN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H26O5/c1-10(2)6-7-12-15(4,21-12)16(19)13(20-5)11(17)8-9-14(16,3)18/h6,12-13,18-19H,7-9H2,1-5H3
|
| Chemical Name |
3,4-dihydroxy-2-methoxy-4-methyl-3-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]cyclohexan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA